Business Model

As the company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV, our mission is to promote our understanding of HBV infection within the scientific community, while also developing and protecting our own intellectual property, in order to accelerate the development of an effective treatment for patients with HBV and HBV/HDV infection.

Replicor has been responsible for several important discoveries in the field:

  • The development of the first class of therapeutic agents (NAPs) that can clear serum HBsAg from the blood of patients.
  • The first observation that the underlying immune function of patients with chronic HBV infection (unmasked for the first time by the removal of HBsAg) is highly variable, highlighting the need for immunotherapy to achieve high rates of functional cure.
  • The first observation in patients that the beneficial effects of immunotherapy are actually suppressed by circulating HBsAg and that the removal of HBsAg leads to a dramatic improvement in the effect of immunotherapy.
  • The achievement of SVR will likely be enhanced by the complete elimination (not just the reduction) of surface antigen. This will require a multi-log reduction of surface antigen.